Baloxavir Marboxil
🔹 Product Overview
A novel single-dose oral antiviral targeting influenza A/B viruses. As a cap-dependent endonuclease inhibitor, it blocks viral RNA replication, offering rapid symptom relief (within 48 hours) and reducing transmission risk13. Widely used in influenza treatment and outbreak prevention across hospitals, clinics, and community settings25.
Google Keywords: Single-Dose Flu Treatment, Cap-Dependent Endonuclease Inhibitor, Influenza Antiviral Drug
🔹 Key Advantages
📌 1. Rapid & Convenient Therapy
Single oral dose achieves full therapeutic effect, eliminating multi-day dosing.
Reduces symptom duration by 30–50%vs. placebo in clinical trials.
📌 2. Precision Mechanism
Targets viral cap-dependent endonuclease, minimizing host cell toxicity.
📌 3. Global Quality Compliance
Manufactured under USP/EP standards, ensuring batch-to-batch consistency.
🔹 Applications
✅ Treatment: Acute uncomplicated influenza in adults and adolescents25.
✅ Prevention: Post-exposure prophylaxis in high-risk populations2.
✅ Public Health: Outbreak control in closed settings (e.g., schools, nursing homes)5.
🔹 Quality Certifications
- USP-NF Monograph compliant (purity ≥99.5%).
- EP 11.0 specifications validated via HPLC and mass spectrometry.
🔹 Market Trends
The global influenza antiviral market is projected to grow at 6.8% CAGR (2025–2030), driven by rising pandemic preparedness and demand for fast-acting therapies4. Baloxavir holds ~25% market share in next-gen influenza treatments due to its dosing advantage24.
Optimized for Search: Influenza Antiviral API, USP-Grade Baloxavir, Single-Dose Antiviral Supplier
Note: Data sourced from clinical trials and pharmacopeial guidelines. Contact for COA and regulatory support.
China
